|
|||||
|
|
||||||
Journal of Clinical Oncology, Vol 23, No 30 (October 20), 2005: pp. 7654-7659 © 2005 American Society of Clinical Oncology. DOI: 10.1200/JCO.2005.01.4340 Improved Detection of Second Primary Cancer Using Integrated [18F] Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for Initial Tumor StagingFrom the Departments of Nuclear Medicine, Radiology, Medicine, Thoracic Surgery, and Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Address reprint requests to Byung-Tae Kim, MD, Department of Nuclear Medicine, Samsung Medical Center, 50 Ilwon-dong, Kangnam-ku 135-710 Seoul Republic of Korea; e-mail: btnm.kim{at}samsung.com PURPOSE: This study evaluated prospectively the value of integrated whole-body positron emission tomography and computed tomography (PET/CT) using [18F] fluorodeoxyglucose (FDG) in detecting a second primary cancer at the time of the initial staging in comparison with a conventional staging work-up (CSW). METHODS: The participants were 547 patients diagnosed with cancer who underwent FDG PET/CT imaging for the initial staging. An additional diagnostic evaluation was performed when there were abnormal findings indicative of a second primary cancer on either PET/CT or CSW considering the site and the biologic behavior of the alleged primary tumor. RESULTS: A total of 27 second primary malignant tumors were identified in 26 of the 547 patients (4.8%). FDG PET/CT found 45 lesions indicative of a second primary cancer, of which 24 lesions were proved to be a second primary cancer, seven were clinically unexpected metastases, and 14 lesions were benign. Therefore, sensitivity and positive predictive value of FDG PET/CT in detecting a second primary cancer or an unexpected metastasis were 91% (31 of 34) and 69% (31 of 45), respectively. In contrast, CSW could not identify 16 second primary cancers and one metastatic lesion. CONCLUSION: FDG PET/CT at the time of the initial staging is useful for screening a second primary cancer with a high sensitivity. An additional diagnostic work-up is essential when abnormal findings, which are indicative of a second primary cancer, are obtained on PET/CT images to rule out the presence of either a second primary cancer or an unexpected metastasis. Presented in part at the Annual Meeting of the Society of Nuclear Medicine, Philadelphia, PA, June 19-23, 2004. Supported by Grant No. 02-PJ3-PG6-EV06-0002 from the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea. Authors' disclosures of potential conflicts of interest are found at the end of this article. This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|